"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04343092","Efficacy of Ivermectin as Add on Therapy in COVID19 Patients",,"Completed","No Results Available","COVID 19","Drug: Ivermectin (IVM)","Number of cured patients|Mean time to cure of the covid 19 patients","University of Baghdad","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO20040001","April 18, 2020","May 31, 2020","June 1, 2020","April 13, 2020",,"June 5, 2020","General Directorate of Medical City, Bagdad, Baghdad, Iraq",,"https://ClinicalTrials.gov/show/NCT04343092"
2,"NCT04373824","Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study",,"Recruiting","No Results Available","COVID","Drug: Ivermectin","effect of Ivermectin on eradication of virus.","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHC-COVID-19- INV- ACT-BHR","April 25, 2020","July 25, 2020","July 25, 2020","May 4, 2020",,"May 4, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04373824"
3,"NCT04392713","Efficacy of Ivermectin in COVID-19",,"Recruiting","No Results Available","COVID","Drug: Ivermectin 6 MG Oral Tablet (2 tablets)","Negative PCR|Need for mechanical ventilation","Combined Military Hospital, Pakistan","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVE-COV","April 15, 2020","July 2020","July 2020","May 19, 2020",,"May 19, 2020","Combined Military Hospital Lahore, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04392713"
4,"NCT04403555","Ivermectin and Doxycycine in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID","Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine","The number of patients with resolved viral infection","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","tanta combo covid treatment","June 1, 2020","December 1, 2030","December 3, 2030","May 27, 2020",,"May 27, 2020","Sherief Abd-Elsalam, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04403555"
5,"NCT04422561","Prophylactic Ivermectin in COVID-19 Contacts",,"Recruiting","No Results Available","COVID","Drug: Ivermectin Tablets","appearance of symptoms ( fever ,cough, sore throat, myalgia,diarrhea, shortness of breath)|development of COVID","Zagazig University","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ZU-IRB#6150l31-5-2020","May 31, 2020","June 2020","July 2020","June 9, 2020",,"June 9, 2020","Zagazig University, Zagazig, Sharkia, Egypt",,"https://ClinicalTrials.gov/show/NCT04422561"
6,"NCT04351347","The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Nitazoxanide|Drug: Ivermectin","Number of patients with virological cure","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ivermecin covid","April 17, 2020","December 1, 2030","December 1, 2030","April 17, 2020",,"April 17, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04351347"
7,"NCT04399746","Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19","IvAzCol","Recruiting","No Results Available","COVID","Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol","Viral clearance|Symptoms duration|SpO2|SpO2/FiO2","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IvAzCol","March 15, 2020","May 20, 2020","June 10, 2020","May 22, 2020",,"May 22, 2020","Outpatient treatment, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04399746"
8,"NCT04381884","Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19 Drug Treatment","Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.","Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2","Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVM-AR-1","May 18, 2020","June 30, 2020","June 30, 2020","May 11, 2020",,"May 27, 2020","Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04381884"
9,"NCT04360356","Ivermectin and Nitazoxanide Combination Therapy for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care","Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients","Tanta University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IVR/NTZ","May 2020","October 2020","December 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04360356"
10,"NCT04374279","Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy","RECOVER","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Ivermectin 3Mg Tab","Number of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV2003|IRB00249425","June 2020","June 2021","June 2021","May 5, 2020",,"May 5, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04374279"
11,"NCT04392427","New Antiviral Drugs for Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID|Drug Effect","Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :","negative test result for COVID-19","Mansoura University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","20.05.69","May 2020","May 2022","May 2022","May 18, 2020",,"May 18, 2020","Mansoura University, Mansoura, Select A State Or Province, Egypt",,"https://ClinicalTrials.gov/show/NCT04392427"
12,"NCT04391127","Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo","Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization","Centenario Hospital Miguel Hidalgo","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2020-A-09","May 4, 2020","August 30, 2020","September 30, 2020","May 18, 2020",,"May 27, 2020","Jose Manuel Arreola Guerra, Aguascalientes, Mexico",,"https://ClinicalTrials.gov/show/NCT04391127"
13,"NCT04405843","Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ivermectin Oral Product|Drug: Placebo","Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention","Centro de Estudios en Infectogía Pediatrica","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ScDi823","June 2020","October 2020","November 1, 2020","May 28, 2020",,"May 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04405843"
14,"NCT04407130","Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.",,"Not yet recruiting","No Results Available","COVID-19 Patients","Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo","Virological clearance|Remission of fever|Remission of cough|Patients requiring oxygen|Patients failing to maintain SpO2 >88% despite oxygenation|Number of days on oxygen support|Chest X-ray improvement|Duration of hospitalization|All causes of mortality","International Centre for Diarrhoeal Disease Research, Bangladesh","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PR-20039","June 2020","July 2020","July 2020","May 29, 2020",,"June 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04407130"
15,"NCT04390022","Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial","SAINT","Recruiting","No Results Available","Covid-19|Coronavirus Infection|SARS-CoV-2 Infection","Drug: Ivermectin|Drug: Placebo","Proportion of patients with a positive SARS-CoV-2 PCR|Mean viral load|Fever and cough progression|Seroconversion at day 21|Proportion of drug-related adverse events|Levels of IgG, IgM and IgA|Frequency of innate immune cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells|Results from cytokine Human Magnetic 30-Plex Panel","Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health","All","18 Years to 59 Years   (Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SAINT","May 14, 2020","August 4, 2020","August 30, 2020","May 15, 2020",,"May 21, 2020","Clinica Universidad de Navarra, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT04390022"
16,"NCT04407507","Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","SILVERBULLET","Not yet recruiting","No Results Available","COVID-19","Drug: Ivermectin|Drug: Placebo","Participants with a disease control status defined as no disease progression to severe.","Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","SARS-COV-IverMX-01","June 2020","August 2020","October 2020","May 29, 2020",,"May 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04407507"
17,"NCT04382846","Novel Regimens in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID|Corona Virus Infection","Drug: Nitazoxanide|Drug: Ivermectin|Drug: Chloroquine|Drug: Azithromycin","Number of patients with virological cure","Tanta University","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","tanta covid treatment","May 8, 2020","December 1, 2030","December 1, 2030","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382846"
18,"NCT04374019","Novel Agents for Treatment of High-risk COVID-19 Positive Patients",,"Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate","Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function","Susanne Arnold|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20-COVID-01-PMC","May 1, 2020","May 2021","May 2021","May 5, 2020",,"May 7, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04374019"
19,"NCT04345419","A Real-life Experience on Treatment of Patients With COVID 19",,"Not yet recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Favipiravir|Drug: Nitazoxanide|Drug: Ivermectin|Drug: Niclosamide|Drug: Other drugs","Number of patients with decreased viral load","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","COVID 19 treatment","April 30, 2020","December 2029","December 2029","April 14, 2020",,"April 29, 2020","Tanta university hospital, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04345419"
